IL17A and colitis: MSC-Ex ameliorates the clinical parameters in DSS-induced colitis; the treated group showed significantly less MPO activity. The level of IL-17 was significantly decreased, whereas those of IL-10 and TGF-Beta1 were increased. MSC-Ex is superior to UC-MSC in chronic IBD models, without differences in the colon length.